QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million

Bulletin Express07-07

Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as treasury stock.

Following the transaction, outstanding shares (excluding treasury shares) declined by 0.0036 % to 223.37 million. Treasury shares increased to 3.70 million, while the company’s total issued share count remained unchanged at 227.07 million.

The buyback forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 22.44 million shares. To date, QYUNS-B has repurchased 0.99 million shares under this mandate, equivalent to 0.44 % of issued shares at the time of approval. In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 6 August 2026.

Board Secretary and Joint Company Secretary Hu Yanbao confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the previously filed explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117526813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117526813","market":"us","top_or_hot":-1,"title":"QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as treasury stock.</p>\n<p>Following the transaction, outstanding shares (excluding treasury shares) declined by 0.0036 % to 223.37 million. Treasury shares increased to 3.70 million, while the company’s total issued share count remained unchanged at 227.07 million.</p>\n<p>The buyback forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 22.44 million shares. To date, QYUNS-B has repurchased 0.99 million shares under this mandate, equivalent to 0.44 % of issued shares at the time of approval. In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 6 August 2026.</p>\n<p>Board Secretary and Joint Company Secretary Hu Yanbao confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the previously filed explanatory statement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-07 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as treasury stock.</p>\n<p>Following the transaction, outstanding shares (excluding treasury shares) declined by 0.0036 % to 223.37 million. Treasury shares increased to 3.70 million, while the company’s total issued share count remained unchanged at 227.07 million.</p>\n<p>The buyback forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 22.44 million shares. To date, QYUNS-B has repurchased 0.99 million shares under this mandate, equivalent to 0.44 % of issued shares at the time of approval. In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 6 August 2026.</p>\n<p>Board Secretary and Joint Company Secretary Hu Yanbao confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the previously filed explanatory statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1117526813","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117526813","pubTimestamp":1783422311,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"QYUNS-B回购8,000股H股，库存股增至370万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) executed an on-market repurchase of 8,000 H shares on 7 July 2026 at HKD 15.70 per share, spending HKD 0.13 million. All repurchased shares were retained as treasury stock.\nFollowing the transaction, outstanding shares (excluding treasury shares) declined by 0.0036 % to 223.37 million. Treasury shares increased to 3.70 million, while the company’s total issued share count remained unchanged at 227.07 million.\nThe buyback forms part of the mandate approved on 29 May 2026, which authorises repurchases of up to 22.44 million shares. To date, QYUNS-B has repurchased 0.99 million shares under this mandate, equivalent to 0.44 % of issued shares at the time of approval. In accordance with Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 6 August 2026.\nBoard Secretary and Joint Company Secretary Hu Yanbao confirmed that the repurchase complied with Main Board Rule 10.06 and that no material changes have been made to the previously filed explanatory statement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117526813","isCrawlerRequest":true}